Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Arm bone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,048 result(s) found for: Arm bone. Displaying page 1 of 53.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-009374-27 Sponsor Protocol Number: 20080540 Start Date*: 2009-08-27
    Sponsor Name:Amgen Inc
    Full Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects with Advanced Cancer or Multiple Myeloma
    Medical condition: Bone metastases in subjects with advanced cancer or multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-006031-30 Sponsor Protocol Number: GIM8 OVER Start Date*: 2007-12-20
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: A Randomized Trial with factorial Design comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in metastatic breast cancer progressing after Aromatase Inhibitor therapy
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001621-94 Sponsor Protocol Number: 2007-1805 Start Date*: 2007-08-11
    Sponsor Name:Lothian Health Board [...]
    1. Lothian Health Board
    2. University of Edinburgh
    Full Title: Pregabalin Bone Trial. A double-blind randomised controlled trial of pregabalin versus placebo in conjunction with palliative radiotherapy for malignant bone pain.
    Medical condition: The condition under investigation is cancer induced bone pain (CIBP). This is a major cause of morbidity in patients with cancer and unfortunately standard treatments (including radiotherapy) can b...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027452 Metastases to bone PT
    9.1 10033372 Pain and discomfort NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000431-32 Sponsor Protocol Number: ORTHOUNION Start Date*: 2017-05-25
    Sponsor Name:Universidad Autónoma de Madrid (U.A.M.)
    Full Title: A MULTI-CENTRE, OPEN-LABEL, RANDOMIZED, COMPARATIVE CLINICAL TRIAL OF TWO DIFFERENT DOSES OF BONE MARROW AUTOLOGOUS HUMAN MESENCHYMAL STEM CELLS PLUS BIOMATERIAL VERSUS ILIAC CREST AUTOLOGOUS GRAFT...
    Medical condition: Diaphyseal and/or metaphysodiaphyseal fractures (femur, tibia, humerus) with status of non-union
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10017085 Fracture malunion PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) FR (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000079-35 Sponsor Protocol Number: J2J-OX-JZLC Start Date*: 2021-11-02
    Sponsor Name:Eli Lilly and Company
    Full Title: EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Neg...
    Medical condition: Breast Neoplasms, Neoplasm Metastasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Ongoing) CZ (Completed) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000810-12 Sponsor Protocol Number: CO41101 Start Date*: 2019-12-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR META...
    Medical condition: Metastatic triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) AT (Completed) PL (Completed) PT (Completed) IE (Prematurely Ended) ES (Completed) FI (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended) BG (Completed) DK (Completed) RO (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000793-30 Sponsor Protocol Number: IntReALL-SR-2010 Start Date*: 2013-10-25
    Sponsor Name:Charité - University Hospital of Berlin
    Full Title: International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
    Medical condition: Acute lymphoblastic leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10063626 Acute lymphocytic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) AT (Completed) IE (Completed) FI (Completed) DK (Completed) CZ (Completed) IT (Completed) NL (Completed) FR (Completed) PL (Completed) ES (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2007-001041-17 Sponsor Protocol Number: 20060289 Start Date*: 2007-09-11
    Sponsor Name:Amgen Inc.
    Full Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis
    Medical condition: Treatment of postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) SE (Completed) EE (Completed) DE (Completed) LV (Completed) GB (Completed) LT (Completed) HU (Completed) AT (Completed) FI (Completed) BE (Completed) MT (Completed) CZ (Completed) FR (Completed) ES (Completed) GR (Completed) IT (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-004765-42 Sponsor Protocol Number: CZOL446GGB12 including amd 1 Start Date*: 2006-05-03
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: An Open label Randomised, multicentre study to evaluate the efficacy of two Zometa (Zoledronic acid) schedules on bone mineral density in prostrate cancer patients undergoing Androgen deprivation T...
    Medical condition: Decreased bone mineral density in prostate cancer patients being treated with ADT
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001855-12 Sponsor Protocol Number: BO 18040 Start Date*: 2004-02-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, placebo controlled study to compare the efficacy of IV loading doses followed by maintenance treatment with IV ibandronic acid versus zoledronic acid in patients with skeletal ...
    Medical condition: Metastatic Bone Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001854-10 Sponsor Protocol Number: BO18039 Start Date*: 2005-02-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in...
    Medical condition: Metastatic Bone Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005582-73 Sponsor Protocol Number: ACE-CL-007 Start Date*: 2015-07-03
    Sponsor Name:Acerta Pharma BV
    Full Title: A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previ...
    Medical condition: Untreated Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004879-13 Sponsor Protocol Number: UKF2013/12 Start Date*: 2014-12-08
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: α-RT; Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. EBRT alone in the treatment of advanced castr...
    Medical condition: Bone metastases in advanced castration resistant prostate carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001101-10 Sponsor Protocol Number: CZOL446G2419 Start Date*: 2004-11-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancer
    Medical condition: Patients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) AT (Completed) IT (Prematurely Ended) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000412-30 Sponsor Protocol Number: LF111/401 Start Date*: Information not available in EudraCT
    Sponsor Name:Chemo Research S.L.
    Full Title: A multicenter, open-label, controlled study to investigate the effect of either LF111 or Drospirenone chewable tablets on bone mineral density (BMD) in adolescent and adult women in comparison with...
    Medical condition: Oral contraception
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10049470 Bone density decreased PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001645-41 Sponsor Protocol Number: 19-339A(3) Start Date*: 2020-03-27
    Sponsor Name:Memorial Sloan Kettering Cancer center
    Full Title: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clin...
    Medical condition: Newly diagnosed Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002089-11 Sponsor Protocol Number: CMBG453B12301 Start Date*: 2020-06-23
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodyspla...
    Medical condition: adult subjects with intermediate, high or very high risk (per IPSS-R prognostic risk categories) myelodysplastic syndrome or with Chronic Myelomonocytic Leukemia - 2 (CMML-2)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) IT (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) FI (Prematurely Ended) LT (Completed) NL (Prematurely Ended) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002443-28 Sponsor Protocol Number: ACE-CL-311/D8221C00001 Start Date*: 2019-05-08
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investiga...
    Medical condition: Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) HU (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000301-71 Sponsor Protocol Number: TJB1117P1 Start Date*: 2013-01-25
    Sponsor Name:CHU-ULg
    Full Title: Donor Regulatory T cells (Treg) infusion (DTI) in patients with steroid-refractory chronic graft-versus-host disease (GVHD).
    Medical condition: Steroid-refractory chronic graft-versus-host-disease.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004047-23 Sponsor Protocol Number: 273551-2 Start Date*: 2019-12-05
    Sponsor Name:University of Bergen
    Full Title: Evaluation of safety and feasibility of autologous MSCs combined to biomaterial to enhance bone healing in patients with delayed consolidation after long bone defects requiring graft apposition or ...
    Medical condition: Diaphyseal and/or metaphysodiaphyseal fractures (femur, tibia, humerus) status delayed union (after 3 months) treated by standard care procedures
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:21:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA